Warning! GuruFocus detected
2 Severe warning signs
with M12.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
M1 Kliniken AG
ISIN : DE000A0STSQ8
Compare
Compare
Traded in other countries / regions
M12.GermanyMKLNF.USA IPO Date
2015-09-14Description
M1 Kliniken AG is a healthcare company operating in the market for aesthetic medical treatment and plastic surgery. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.37 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.3 | |||||
| Interest Coverage | 12.23 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.84 | |||||
| Beneish M-Score | -2.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.3 | |||||
| 3-Year EBITDA Growth Rate | 16.1 | |||||
| 3-Year EPS without NRI Growth Rate | 17.5 | |||||
| 3-Year FCF Growth Rate | -7.4 | |||||
| 3-Year Book Growth Rate | 8.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.64 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.73 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.88 | |||||
| 9-Day RSI | 58.75 | |||||
| 14-Day RSI | 54.93 | |||||
| 3-1 Month Momentum % | -12.65 | |||||
| 6-1 Month Momentum % | -15.2 | |||||
| 12-1 Month Momentum % | 10.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.76 | |||||
| Quick Ratio | 1.1 | |||||
| Cash Ratio | 0.4 | |||||
| Days Inventory | 48.45 | |||||
| Days Sales Outstanding | 33.38 | |||||
| Days Payable | 34.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.36 | |||||
| Forward Dividend Yield % | 3.36 | |||||
| 5-Year Yield-on-Cost % | 3.36 | |||||
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | 10.16 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 17.42 | |||||
| Operating Margin % | 6.55 | |||||
| Net Margin % | 5.03 | |||||
| FCF Margin % | 5.62 | |||||
| ROE % | 15.67 | |||||
| ROA % | 8.12 | |||||
| ROIC % | 11.48 | |||||
| 3-Year ROIIC % | 22.41 | |||||
| ROC (Joel Greenblatt) % | 64.92 | |||||
| ROCE % | 17.07 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.76 | |||||
| Forward PE Ratio | 15.5 | |||||
| PE Ratio without NRI | 18.65 | |||||
| Shiller PE Ratio | 32.12 | |||||
| Price-to-Owner-Earnings | 28.88 | |||||
| PEG Ratio | 1.48 | |||||
| PS Ratio | 0.85 | |||||
| PB Ratio | 2.61 | |||||
| Price-to-Tangible-Book | 13.19 | |||||
| Price-to-Free-Cash-Flow | 14.97 | |||||
| Price-to-Operating-Cash-Flow | 14.04 | |||||
| EV-to-EBIT | 11.38 | |||||
| EV-to-EBITDA | 9.52 | |||||
| EV-to-Revenue | 0.9 | |||||
| EV-to-FCF | 15.98 | |||||
| Price-to-GF-Value | 1.46 | |||||
| Price-to-Projected-FCF | 1.65 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.36 | |||||
| Price-to-Graham-Number | 3.3 | |||||
| Price-to-Net-Current-Asset-Value | 45.15 | |||||
| Earnings Yield (Greenblatt) % | 8.79 | |||||
| FCF Yield % | 6.57 | |||||
| Forward Rate of Return (Yacktman) % | 15.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
M1 Kliniken AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 333.266 | ||
| EPS (TTM) (€) | 0.889 | ||
| Beta | 0.88 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 1.41 | ||
| Volatility % | 62.43 | ||
| 14-Day RSI | 54.93 | ||
| 14-Day ATR (€) | 0.422126 | ||
| 20-Day SMA (€) | 14.515 | ||
| 12-1 Month Momentum % | 10.69 | ||
| 52-Week Range (€) | 11.8 - 22.4 | ||
| Shares Outstanding (Mil) | 19.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
M1 Kliniken AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
M1 Kliniken AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
M1 Kliniken AG Frequently Asked Questions
What is M1 Kliniken AG(XTER:M12)'s stock price today?
The current price of XTER:M12 is €14.90. The 52 week high of XTER:M12 is €22.40 and 52 week low is €11.80.
When is next earnings date of M1 Kliniken AG(XTER:M12)?
The next earnings date of M1 Kliniken AG(XTER:M12) is .
Does M1 Kliniken AG(XTER:M12) pay dividends? If so, how much?
The Dividend Yield %  of M1 Kliniken AG(XTER:M12) is 3.36% (As of Today), Highest Dividend Payout Ratio of M1 Kliniken AG(XTER:M12) was 0.91. The lowest was 0.73. And the median was 0.78. The  Forward Dividend Yield % of M1 Kliniken AG(XTER:M12) is 3.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers